Reneuron gets US patent for non-toxic cell cryopreservation system

By Gareth Macdonald contact

- Last updated on GMT

Reneuron gets US patent for cryopreservation tech
Reneuron gets US patent for cryopreservation tech

Related tags: Stem cell

Reneuron has been granted a US patent for a cryopreservation technology that does not rely on toxic reagents and says it would consider licensing it to other stem cell therapy developers on a case-by-case basis.

The patent – no. 13/132,475 – covers technology that can freeze and thereby extend the shelf life of the neural, retinal and mesenchymal cells according to Reneuron.

A spokesman told us the technology is used to “freeze the cells in order that they can be readily shipped and stored with a long shelf life​” adding that  “they are then thawed at the site and administered when required​.”

Reneuron said the tech in question is a “formulation” but did not go into additional details.

The spokesman did say that: “We have developed our own formulation which is optimal for our cells and avoids the need for toxic cryopreservants typically found in marketed solutions​.”

Clinical trial

Reneuron has used the technology to develop an extended shelf life version of its ischemic stroke therapy – CTX stem cell. The developmental therapy is made at Reneuron's facility in Pencoed, Wales and distributed to clinical trial sites across the UK.

Last August​, the firm installed new processing technology to automate production of CTX ahead of late phase trials. The cryopreservation technology covered by the new US patent is a further effort to streamline the manufacturing process.

However, the US patent does open up other possibilities for Reneruon beyond protecting its own cell therapy products.

The firm’s spokesman told us “The primary purpose of the patent is to protect our technology assets.  Should a third party wish to utilise the technology, we would consider granting licenses on a case-by-case basis​.”

Related topics: Downstream Processing, Cell lines

Related news

Show more

Related products

show more

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Nifty Biosimilar

Nifty Biosimilar

UGA Biopharma | 13-Mar-2018 | Research Study

Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development...

Related suppliers

Follow us

Products

View more

Webinars